Financial Performance - Revenue for the third quarter was RMB 485,799,506.29, a decrease of 15.51% compared to the same period last year[4] - Net profit attributable to shareholders was RMB 99,435,565.54, down 58.04% year-on-year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 84,926,745.33, a decline of 63.74% compared to the previous year[4] - The net cash flow from operating activities was RMB 192,325,709.34, a decrease of 57.11% year-on-year[4] - Basic earnings per share were RMB 0.13, down 59.38% compared to the same period last year[4] - Net profit attributable to shareholders decreased by 121.46% year-to-date due to intensified competition, declining sales revenue, and a decrease in the fair value of biological assets[11] - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 136.47% year-to-date, primarily due to similar factors as above[11] - Cash flow from operating activities decreased by 57.11% year-to-date, mainly due to reduced sales collections while employee compensation remained stable compared to the previous year[11] - Basic earnings per share decreased by 120.45% year-to-date, reflecting the impact of increased competition and declining sales revenue and gross margin[11] - Diluted earnings per share decreased by 120.45% year-to-date, consistent with the basic earnings per share decline[11] - Net profit attributable to shareholders for the current reporting period decreased by 58.04% due to intensified competition and declining sales revenue[11] - Net profit attributable to shareholders after deducting non-recurring gains and losses for the current reporting period decreased by 63.74%[11] - Basic earnings per share for the current reporting period decreased by 59.38% due to similar competitive pressures[11] - Diluted earnings per share for the current reporting period decreased by 59.38%, reflecting the same trends[11] Assets and Liabilities - Total assets at the end of the reporting period were RMB 9,525,184,807.98, a decrease of 5.01% from the end of the previous year[4] - Equity attributable to shareholders was RMB 8,002,435,682.20, down 3.34% compared to the end of the previous year[4] - As of September 30, 2024, the company's total current assets amounted to RMB 5.33 billion, a decrease from RMB 7.12 billion on December 31, 2023[18] - The total non-current assets as of September 30, 2024, were CNY 4,191,072,779.02, significantly higher than CNY 2,905,192,290.36 as of December 31, 2023, marking an increase of about 44.2%[21] - Total liabilities as of September 30, 2024, were CNY 1,534,350,209.75, down from CNY 1,746,119,215.39 at the end of 2023, a decrease of approximately 12.1%[20] - The total assets as of September 30, 2024, were CNY 9,525,184,807.98, compared to CNY 10,027,159,630.47 at the end of 2023, indicating a decline of about 5.0%[21] - The total equity attributable to shareholders as of September 30, 2024, was CNY 8,002,435,682.20, down from CNY 8,279,315,724.35 at the end of 2023, a decrease of about 3.4%[21] Cash Flow and Investments - The company's cash and cash equivalents decreased from RMB 2.86 billion at the end of 2023 to RMB 1.84 billion as of September 30, 2024[18] - The company's trading financial assets increased significantly from RMB 373.35 million to RMB 1.38 billion during the same period[18] - The company reported a net interest income of CNY 82,526,990.66 for the first three quarters of 2024, compared to CNY 108,316,598.07 in the same period of 2023, reflecting a decrease of approximately 23.9%[22] - Cash inflow from operating activities for the first three quarters of 2024 is 1,367,691,390.73, down from 1,874,131,001.01 in 2023, showing a decrease in cash generation[27] - The cash inflow from investment activities totaled 2,508,098,115.21, significantly increasing from 528,639,464.14 in the first three quarters of 2023[28] - The net cash flow from investment activities was -950,050,766.71, worsening from -137,147,755.87 in the same period of 2023[28] - The cash outflow from financing activities was 248,828,091.97, down from 333,289,197.75 in the first three quarters of 2023[29] - The net increase in cash and cash equivalents was -1,013,522,516.10, compared to -8,194,783.60 in the same period of 2023[29] - The ending balance of cash and cash equivalents was 1,840,124,511.87, a decrease from 2,891,274,796.93 at the end of the same period in 2023[29] - The cash inflow from recovering investments was 2,307,885,508.22, a substantial increase from 501,496,756.80 in the first three quarters of 2023[28] - The cash outflow for purchasing fixed assets and intangible assets was 188,019,727.66, up from 149,651,195.84 in the same period of 2023[28] - The cash paid for long-term assets was 3,270,129,154.26, significantly higher than 426,076,500.00 in the first three quarters of 2023[28] Operational Performance - The company signed new contracts worth approximately RMB 1.4 billion in the first three quarters, with a total order backlog of about RMB 2.65 billion as of the end of the reporting period[16] - The company reported a foreign exchange loss of -190,401,449.68 in the first three quarters of 2024, compared to -108,513,934.09 in 2023, indicating increased volatility in currency exchange[23] - The company experienced a credit impairment loss of -11,477,062.92 in the first three quarters of 2024, compared to -3,187,147.18 in 2023, reflecting worsening credit conditions[23] - The operating profit for the first three quarters of 2024 is -69,661,013.72, down from 392,084,940.00 in 2023, indicating a substantial decrease in operational performance[23] - The total comprehensive income for the first three quarters of 2024 is -79,103,195.69, a stark contrast to 336,381,200.67 in the previous year[25] - Basic and diluted earnings per share for the first three quarters of 2024 are both reported at -0.09, compared to 0.44 in 2023, indicating a loss per share[25] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 72,246, with the top ten shareholders holding significant stakes[12] - There were no changes in the top 10 shareholders due to securities lending or borrowing activities[15] Strategic Outlook - The company has not disclosed any new product or technology developments in the recent reporting period[16] - The company has not indicated any market expansion or acquisition strategies in the latest report[16] - The company has advised investors to be cautious due to various factors affecting order execution[16]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，於 第 四 屆 董 事 會 第 十 次 會 議 中，董 事 會 決 議 及 批 准（其 中 包 括）：(i)建 議 變 更 本 公 司 註 冊 股 本；及(ii)建議修訂本公司組織章程細則（「組織章程細則」）。 建議變更本公司註冊股本 由於包括(i)儲 備 資 本 化；(ii)根 據2019年A股限制性股票激勵計劃及2021年A股 限 制性股票激勵計劃購回及註銷A股 限 制 性 股 票；及(iii)終 止2021年A股限制性股 票 激 勵 計 劃，並 購 回 及 註 銷 其 項 下 已 授 出 但 尚 未 解 除 限 售 的A股限制性股票等 因 素，本 公 司 的 註 冊 股 本 ...

北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） JOINN LABORATORIES (CHINA) CO., LTD. | | 董事委員會 | | 薪酬與考核 | | | | --- | --- | --- | --- | --- | --- | | 董事 | | 戰略委員會 | 委員會 | 審計委員會 | 提名委員會 | | 執行董事 | | | | | | | 馮宇霞女士 | （主 席） | C | | | M | | 左從林先生 | | M | M | | | | 高大鵬先生 | | | | | | | 孫雲霞女士 | | M | | | | | 獨立非執行董事 | | | | | | | 孫明成先生 | | | M | C | | | 翟永功博士 | | | | M | C | | 歐小傑先生 | | M | C | | M | | 張帆先生 | | | | M | | 附 註： C 相關董事委員會的主席 M 相關董事委員會的成員 中 國，北 京，2024年10月30日 （股 份 代 號：6127） 董事名單以及其角色及職能 北京昭衍 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） (1)執行董事辭任 及 (2)建議委任執行董事 執行董事辭任 北京昭衍新藥研究中心股份有限公司（「本公司」）董 事（「董 事」，各 自 為 一 名「董 事」）會（「董事會」）於近日收到姚大林博士（「姚博士」）的 辭 職 函。據 此，姚 博 士 因 工 作 安 排 辭 去 本 公 司 執 行 董 事 及 本 公 司 副 總 經 理 職 務。姚 博 士 已 確 認，彼 與 董 事 會 並 無 意 見 分 歧，亦 無 其 他 因 辭 任 而 需 知 會 股 東 的 事 宜。姚 博 士 辭 去 上 述 職 務 後，將 繼 續 在 公 司 其 ...

证券简称：昭衍新药 证券代码：603127 公告编号：2024-050 北京昭衍新药研究中心股份有限公司 关于与专业投资机构合作参与投资设立产业基金 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基金名称：服务贸易创新发展引导基金二期（有限合伙）（暂定名，具 体名称以工商行政管理机构核定名称为准） 投资金额：北京昭衍新药研究中心股份有限公司或其指定子公司拟作为 服务贸易创新发展引导基金二期的有限合伙人，认缴出资不超过 1 亿元人民币 相关风险提示：截至本公告日，北京昭衍新药研究中心股份有限公司尚 未与招商局资本管理（北京）有限公司签署《合作协议》，《合作协议》尚需履 行内部流程。该基金尚处于筹备阶段，能否顺利完成设立、备案以及完成时间尚 存在不确定性，设立过程中可能因合伙人未能缴足认缴资金等情形，导致未能成 功募足，实际募集及各方缴付出资情况可能存在不确定性。 为践行国家级基金的政策使命，全方位助力公司业务发展，提升核心竞争力， 经国务院批准，由财政部、商务部与招商局资本管理（北京）有限公司（以下简 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2024-051 北京昭衍新药研究中心股份有限公司 关于董事辞任及补选非独立董事的公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或 者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京昭衍新药研究中心股份有限公司（下称"公司"或"昭衍新药"）董事会于 近日收到姚大林先生辞去董事、副总经理职务的书面辞呈，姚大林先生因个人及 工作原因申请辞去公司董事、副总经理职务。姚大林先生辞去上述职务后，将继 续在公司其他子公司任职。 截至本公告披露日，姚大林先生持有公司 A 股股份 76,458 股。 根据《公司法》《公司章程》等规定，经公司股东提名、董事会提名委员会 资格审核，公司于 2024 年 10 月 30 日召开第四届董事会第十次会议，审议通过 了《关于补选公司第四届董事会非独立董事的议案》，同意补选罗樨女士（简历 附后）为公司第四届董事会非独立董事候选人，任期自股东大会审议通过之日起 至第四届董事会届满之日止。该事项尚需提交公司股东大会审议。 特此公告。 北京昭衍新药研究中心股份有限公司董事会 2024 年 10 月 30 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2024-049 北京昭衍新药研究中心股份有限公司 关于变更公司注册资本并修订公司章程的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 综上，公司的总股份由 535,678,676 股变更为 749,477,334 股，注册资本由 535,678,676 元变更为 749,477,334 元。 由于公司实施资本公积转增股份以及股权激励等因素的影响，公司的总股份 相应发生变化。具体变化如下： 2023 年 7 月，公司回购注销了受 2019 年与 2021 年股权激励限制性股票激 励对象离职与业绩考核不达标等原因失效的 34,401 股限制性股票。注销完成后， 公司总股本由 535,678,676 股减少至 535,644,275 股，注册资本由 535,678,676 元 变更为 535,644,275 元； 2023 年 7 月，公司实施了 2022 年年度利润分配方案，除每股派发现金红利 0.40 元外，同时以资本公积金每股转增 0.4 股，即在公司总股份 535 ...

北京昭衍新药研究中心股份有限公司章程 北京昭衍新药研究中心股份有限公司 章程 二零二四年十月 1 | | 北京昭衍新药研究中心股份有限公司章程 3 | | --- | --- | | 第一章 | 总则 3 | | 第二章 | 经营宗旨和范围 4 | | 第三章 | 股份 5 | | | 第一节 股份发行 5 | | | 第二节 股份增减和回购 7 | | | 第三节 股份转让 10 | | | 第四节 购买公司股份的财务资助 12 | | | 第五节 股票和股东名册 13 | | 第四章 | 股东和股东大会 17 | | | 第一节 股东 17 | | | 第二节 股东大会的一般规定 22 | | | 第三节 股东大会的召集 25 | | | 第四节 股东大会的提案与通知 26 | | | 第五节 股东大会的召开 29 | | | 第六节 股东大会的表决和决议 33 | | | 第七节 类别股东表决的特别程序 38 | | 第五章 | 董事会 41 | | | 第一节 董事 41 | | | 第二节 董事会 45 | | | 第三节 董事会专门委员会 53 | | 第六章 | 总经理及其他高级管理人员 54 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2024-048 北京昭衍新药研究中心股份有限公司 第四届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京昭衍新药研究中心股份有限公司（以下简称"公司"或"昭衍新药"）第四 届董事会第十次会议于 2024 年 10 月 16 日以书面送达、电子邮件等方式发出会 议通知，并于 2024 年 10 月 30 日在公司会议室以现场会议和电话会议的形式召 开。本次会议应参加董事 9 人，实际参加董事 9 人，会议由董事长冯宇霞女士主 持；公司全部监事和部分高级管理人员列席会议。会议的召集和召开及表决符合 《中华人民共和国公司法》和《北京昭衍新药研究中心股份有限公司章程》（以 下简称"《公司章程》"）的规定，会议程序合法、有效。 本次会议经与会董事认真审议，以举手表决方式作出了如下决议： 1.审议通过《关于公司 2024 年第三季度报告的议案》 根据《公司法》《公司章程》等规定，经公司股东提名、董事会提名委员会 资格审核，董事会同意补选罗樨女士为公司第四 ...

Financial Performance - Revenue for Q3 2024 was RMB 485,799,506.29, a decrease of 15.51% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was RMB 99,435,565.54, down 58.04% year-on-year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was RMB 84,926,745.33, a decline of 63.74% compared to the previous year[2] - Year-to-date net profit attributable to shareholders was RMB -70,307,075.11, a decrease of 121.46% compared to the same period last year[2] - Year-to-date revenue was RMB 1,335,156,050.40, down 15.87% year-on-year[2] - Basic earnings per share for Q3 2024 was RMB 0.13, a decrease of 59.38% compared to the same period last year[3] - The net profit for Q3 2024 was -74,244,009.94 RMB, a significant decrease compared to the net profit of 326,197,002.65 RMB in Q3 2023, representing a decline of approximately 122.7%[22] - Operating profit for Q3 2024 was -69,661,013.72 RMB, compared to an operating profit of 392,084,940.00 RMB in the same period last year, indicating a substantial drop[22] - Total operating revenue for the first three quarters of 2024 was CNY 1,335,156,050.40, a decrease of 15.8% compared to CNY 1,587,079,779.38 in the same period of 2023[20] - The total comprehensive income for Q3 2024 was -79,103,195.69 RMB, compared to 336,381,200.67 RMB in Q3 2023, indicating a decline of approximately 123.5%[23] Assets and Liabilities - Total assets at the end of the reporting period were RMB 9,525,184,807.98, a decrease of 5.01% from the end of the previous year[3] - Total assets amounted to CNY 9,525,184,807.98, down from CNY 10,027,159,630.47, a decrease of 5.0%[19] - Total liabilities decreased to CNY 1,534,350,209.75 from CNY 1,746,119,215.39, a reduction of 12.1%[19] - The company's total equity decreased to CNY 7,990,834,598.23 from CNY 8,281,040,415.08, a decline of 3.5%[19] - Inventory decreased to CNY 1,631,793,427.45 from CNY 1,863,081,944.56, a decrease of 12.4%[18] Cash Flow - The net cash flow from operating activities year-to-date was RMB 192,325,709.34, down 57.11% year-on-year[2] - The cash flow from operating activities for the first three quarters of 2024 was 192,325,709.34 RMB, a decrease from 448,440,218.42 RMB in the same period of 2023, showing a decline of approximately 57.1%[24] - The total cash inflow from investment activities for the first three quarters of 2024 was 2,508,098,115.21 RMB, a significant increase from 528,639,464.14 RMB in the same period of 2023[24] - The net cash flow from investing activities was -950,050,766.71, compared to -137,147,755.87 in the previous period, indicating a significant increase in cash outflow for investments[25] - The total cash outflow from financing activities was 248,828,091.97, down from 333,289,197.75 in the previous period, reflecting a reduction in financing costs[25] - The net increase in cash and cash equivalents was -1,013,522,516.10, compared to -8,194,783.60 in the previous period, showing a substantial decline in liquidity[25] - The ending balance of cash and cash equivalents was 1,840,124,511.87, down from 2,891,274,796.93 in the previous period, indicating a decrease in available cash[25] Shareholder Information - The total number of common shareholders at the end of the reporting period was 72,246, with no preferred shareholders having voting rights[9] - The largest shareholder, Feng Yuxia, holds 167,160,633 shares, representing 22.30% of the total shares[10] - The second largest shareholder, HKSCC Nominees Limited, holds 118,974,786 shares, accounting for 15.87%[10] - The company has not reported any changes in the top 10 shareholders due to margin trading or stock lending activities during the reporting period[14] - The top 10 shareholders include several institutional investors, with the largest being a medical index fund[12] Business Operations - The contribution of laboratory service business to net profit year-to-date was RMB -1,705,100, a decline of 100.55% compared to the previous year[4] - The fair value change of biological assets resulted in a net loss of RMB 17,698,420.00 year-to-date[4] - The total new signed orders for the first three quarters amounted to approximately RMB 1.4 billion, with the total outstanding orders at approximately RMB 2.65 billion as of the report date[15] - The outstanding orders execution is influenced by various factors, and investors are advised to pay attention to investment risks[15] - The company has not disclosed any new product developments or market expansion strategies in the current report[11] - The company is focusing on expanding its market presence and enhancing its product development capabilities, although specific new products or technologies were not detailed in the report[20] Research and Development - Research and development expenses for Q3 2024 were 71,085,657.06 RMB, down from 77,639,680.27 RMB in Q3 2023, reflecting a decrease of about 8.1%[22] Accounting and Standards - The company’s financial statements are unaudited as of September 30, 2024[16] - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[26]